Your browser doesn't support javascript.
loading
A phase 1b open-label dose-finding study of ustekinumab in young adults with type 1 diabetes.
Marwaha, Ashish K; Chow, Samuel; Pesenacker, Anne M; Cook, Laura; Sun, Annika; Long, S Alice; Yang, Jennie H M; Ward-Hartstonge, Kirsten A; Williams, Evangelia; Domingo-Vila, Clara; Halani, Khalif; Harris, Kristina M; Tree, Timothy I M; Levings, Megan K; Elliott, Thomas; Tan, Rusung; Dutz, Jan P.
Afiliación
  • Marwaha AK; Department of Medical Genetics, University of Calgary, Cumming School of Medicine, Calgary, Alberta, Canada.
  • Chow S; Department of Dermatology and Skin Science, University of British Columbia, Vancouver, British Columbia, Canada.
  • Pesenacker AM; BC Children's Hospital Research Institute, Vancouver, British Columbia, Canada.
  • Cook L; BC Children's Hospital Research Institute, Vancouver, British Columbia, Canada.
  • Sun A; Department of Surgery, University of British Columbia, Vancouver, British Columbia, Canada.
  • Long SA; BC Children's Hospital Research Institute, Vancouver, British Columbia, Canada.
  • Yang JHM; Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
  • Ward-Hartstonge KA; Department of Dermatology and Skin Science, University of British Columbia, Vancouver, British Columbia, Canada.
  • Williams E; BC Children's Hospital Research Institute, Vancouver, British Columbia, Canada.
  • Domingo-Vila C; Benaroya Research Institute at Virginia Mason, Translational Research Program, Seattle, WA, USA.
  • Halani K; Department of Immunobiology, King's College London, London, UK.
  • Harris KM; BC Children's Hospital Research Institute, Vancouver, British Columbia, Canada.
  • Tree TIM; Department of Surgery, University of British Columbia, Vancouver, British Columbia, Canada.
  • Levings MK; Department of Immunobiology, King's College London, London, UK.
  • Elliott T; Department of Immunobiology, King's College London, London, UK.
  • Tan R; Emmes Canada, Burnaby, British Columbia, Canada.
  • Dutz JP; Immune Tolerance Network, Bethesda, MD, USA.
Immunother Adv ; 2(1): ltab022, 2022.
Article en En | MEDLINE | ID: mdl-35072168
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Diagnostic_studies / Prognostic_studies Idioma: En Revista: Immunother Adv Año: 2022 Tipo del documento: Article País de afiliación: Canadá
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Diagnostic_studies / Prognostic_studies Idioma: En Revista: Immunother Adv Año: 2022 Tipo del documento: Article País de afiliación: Canadá